Research analysts at Leerink Partnrs lifted their Q1 2025 earnings estimates for shares of Beam Therapeutics in a research ...

Analysts at Leerink Partnrs issued their FY2024 earnings estimates for shares of Shattuck Labs in a report released on Monday ...

Fintel reports that on March 21, 2025, Leerink Partners downgraded their outlook for Elevation Oncology (NasdaqGS:ELEV) from ...

Leerink Partners analyst Thomas Smith reiterated a Buy rating on Immunovant (IMVT – Research Report) yesterday and set a price target of ...

Leerink downgraded Elevation Oncology (ELEV) to Market Perform from Outperform with a price target of $1, down from $9, after the company ...

Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to ...

Fintel reports that on March 17, 2025, Leerink Partners initiated coverage of Shattuck Labs (NasdaqGS:STTK) with a Outperform ...

Leerink Partners 2025 Global Healthcare Conference Call March 12, 2025 11:20 AM ETCompany ParticipantsRoland Chen ...

today announced its participation in a fireside chat at the Leerink Healthcare Conference on Wednesday, March 12, 2025 at 10:00 a.m. ET. A live webcast will be available on the Investors & Media ...

Capricor management will present updates on its lead program of deramiocel for the treatment of Duchenne muscular dystrophy (DMD) as well as provide other general scientific and corporate updates ...

On Thursday, Leerink Partners maintained a Market Perform rating on Enhabit Home Health & Hospice (NYSE:EHAB), following the company’s fourth-quarter earnings report. The firm noted that Enhabit’s ...

Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 11, 2025. Christoph Brackmann, Chief Financial Officer ...